Country-specific cost-effectiveness of early intervention with budesonide in mild asthma

European Respiratory Journal

Volumn 24, Issue 4, 2004, Pages 568-574

  Buxton, Martin J ^a   Sullivan, S D ^b   Andersson, L F ^e   Lamm, C J ^e   Liljas, B ^e   Busse, W W ^c   Pedersen, S ^f   Weiss, K B ^d,g  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d HINES VA HOSPITAL   (United States)

^e ASTRAZENECA R AND D   (Sweden)

^f KOLDING HOSPITAL   (Denmark)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Budesonide; Cost effectiveness; Early intervention; Inhaled Steroid Treatment As Regualr Therapy in early asthma; International

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR AFFECTING AGENT; PLACEBO; STEROID; XANTHINE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; AUSTRALIA; CANADA; CHILD; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; FRANCE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOCIAL BEHAVIOR; SPAIN; SWEDEN; SYMPTOMATOLOGY; UNITED KINGDOM; UNITED STATES;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ASTHMA; AUSTRALIA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; CHINA; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; PROSPECTIVE STUDIES;

EID: 6444238402     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00108703     Document Type: Article

References (57)

1. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised double-blind trial. Lancet 2003; 361: 1071-1076.
2. Sullivan SD, Buxton M, Andersson LF, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003; 112: 1229-1236.
3. Schulman K, Burke J, Drummond M, et al. Resource costing for multinational neurologic clinical trials: methods and results. Health Economics 1998; 7: 629-638.
4. Gosden TB, Torgerson DJ. Converting international cost effectiveness data to UK prices. BMJ 2002; 325: 275-276.
5. Pauwels RA, Busse WW, O'Byrne RM, et al. The inhaled Steroid Treatment As Regular Therapy in early asthma (START) study: rational and design. Control Clin Trials 2001; 22: 5-19.
6. Sullivan SD, Liljas B, Buxton M, et al. Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial. Control Clin Trials 2001; 22: 20-37.
7. National Institutes of Health. National Asthma Education and Prevention Program Task Force on the Cost Effectiveness, Quality of Care, and Financing of Asthma Care. NHLBI, No. 55-807. Washington DC, National Institutes of Health, 1996.
8. Sullivan SD, Elixhauser A, Buist AS, Luce BR, Eisenberg J, Weiss KB. National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996; 154: 3 Pt 2, S84-S95.
9. Pharmaceutical Benefits Scheme (PBS). Canberra, Australia, 2000.
10. PPS Pharma Publication. Moncton, Total Publishing Systems Inc., January 2000.
11. Shandong Pharmaceutical Distribution Services. Shandong, China, 2000.
12. Vidal, Paris, France, 2000.
13. Ediciones Medicon. Madrid, Spain, 2000.
14. Pharmaceuticals in Sweden. Stockholm, Linfo, Läkemedelsinformation AB, 2000.
15. Monthly Index of Medical Specialities (MIMS). London, Haymarket Publishing Ltd., 2000.
16. Drug Topics Red Book. Montvale, Medical Economics, 2000.
17. National Hospital Cost Data Collection, 1998-1999. Department of Health, Canberra, Australia, 2000.
18. Jacobs P, Bachynsky J, Hall E. A Manual of Standard Costs for Pharmacoeconomic Studies in Canada. Ottawa, Canada, Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1995.
19. Institute of Social Medicine and Health Policy, Shandong Medical University, Shandong, China, 2000.
20. Assistance Publique-Hôpitaux de Paris. Paris, France, 1995.
21. Centre d'Estudis En Economia De La Salut I De La Politica Social SL (SOIKOS). Base de datos de costes sanitaros, Actualization de 1999, Barcelona, Spain. www.soikos.com. 1999.
22. Costs per inpatient: number of days, physician visits, etc. in 1993. Stockholm, The Federation of Swedish County Councils, 1995.
23. Personal Social Services Research Unit (PSSRU). Unit Cost of Health and Social Care. Netten A, Dennett J, Knight J, eds. PSSRU, University of Kent at Canterbury, Canterbury, UK. www.pssru.ac.uk. 2000.
24. PharMetrics Integrated Outcomes Database. 1999.
25. Approach to the Measurement of Costs when Evaluating Health and Social Program. McMaster University, Hamilton, Canada, November 1995.
26. Agence regionale de l'hospitale Ile de France, Paris, France. Programme de Medicalisation du Systeme d'Information (PMSI), 1998.
27. Andersson F, Kartman B. The Cost of Angina Pectoris in Sweden. Pharmaco Economics 1995; 7: 233 244.
28. Medicare Benefit Schedule Book (November 1998). Dept of Health, Canberra, Australia, 1999.
29. Ontario Health Insurance Schedule of Benefits and Fees (February 1, 1998. Revised: April, 1999). Toronto, Canada, 1999.
30. Nomenclature Générale des Actes Professionnels (1998). Paris, France, 1999.
31. The Health Service Financial Database. The Chartered Institute of Public Finance and Accountancy (CIPFA), Institute of Public Finance (IPF). London, UK, 1997.
32. Emolun Hospital, Dept of Health, Paris, France, 1997.
33. New South Wales (NSW) Health Dept. Ambulatory Care Survey of Selected NSW (Public Hospitals: Outpatients Services), Structural and Funding Policy Branch, Sydney, Australia, 1997.
34. Labour Force and Unpaid Work of Canadians. Statistics Canada, Ottawa, Canada, 1996.
35. Direction de la Recherche des Etudes (DREES). France, 1999.
36. Andersson F, Ståhl E, Barnes PJ, et al., for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study. Respir Med 2001; 95: 505-512.
37. Australian Bureau of Statistics. Canberra, Australia, August, 1999.
38. The Daily: Statistics Canada. Ottawa, Canada, 1999.
39. Institut National de la Statistique et des Etudes Economique (INSEE). Paris, France, 1997.
40. Encuesta de estruda salarial. Madrid, Instituto National de Estadistica (INE), Spain, 1995.
41. Statistical yearbook of salaries (1997). Stockholm, Statistics Sweden, 1998.
42. The New Earnings Survey, part A, table 1. Office of National Statistics (ONS), London, UK, 1999.
43. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO. Prevention effectiveness: a guide to decision analysis and prevention effectiveness. Oxford, Oxford University Press, 1996.
44. World Bank. World Development Indicators 2001. Washington DC, The World Bank, 2001.
45. Gerdtham U-G, Jönsson B. Convertion factor instability in international comparisons of health care expenditure. J Health Econ 1991; 10: 227-234.
46. Gold MR, Siegel JE, Russell LB, Weinstein M. Cost-effectiveness in Health and Medicine. New York, Oxford University Press, 1996.
47. Drummond MF, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8: 671-682.
48. Schulman KA, Buxton M, Glick H, et al. Results of the economic evaluation of the first study. A multinational prospective economic evaluation. Int J Technol Assess Health Care 1996; 12: 698-713.
49. O'Brien BJ. A tale of two or more cities: geographic transferability of pharmacoeconomic data. Am J Man Care 1997; 3: S33-S39.
50. Jönsson B, Weinstein M. Economic evaluation alongside multinational clinical trials: study considerations for GUSTO IIb. Int J Technol Assess Health Care 1997; 13: 49-58.
51. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481-493.
52. Koopmanschap MA, Touw KCR, Rutten FFH. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001; 58: 175-186.
53. Rutten-van Mölken MPMH, van Doorslaer EKA, Jansen MC, Kerstjens HAM, Rutten FHF. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975-982.
54. Sullivan SD, Weiss KB, Lynn H, et al. The cost-effectiveness of an inner-city asthma intervention for children. J Allegy Clin Immunol 2002; 110: 576-581.
55. Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001; 108: 39-46.
56. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000; 20: 451-467.
57. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323: 1300-1303.